Literature DB >> 22118987

Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study.

Benjamin Waschki1, Martijn A Spruit, Henrik Watz, Paul S Albert, Dinesh Shrikrishna, Miriam Groenen, Cayley Smith, William D-C Man, Ruth Tal-Singer, Lisa D Edwards, Peter M A Calverley, Helgo Magnussen, Michael I Polkey, Emiel F M Wouters.   

Abstract

BACKGROUND: Little is known about COPD patients' compliance with physical activity monitoring and how activity relates to disease characteristics in a multi-center setting.
METHODS: In a prospective study at three Northern European sites physical activity and clinical disease characteristics were measured in 134 COPD patients (GOLD-stage II-IV; BODE index 0-9) and 46 controls. Wearing time, steps per day, and the physical activity level (PAL) were measured by a multisensory armband over a period of 6 consecutive days (in total, 144 h). A valid measurement period was defined as ≥22 h wearing time a day on at least 5 days.
RESULTS: The median wearing time was 142 h:17 min (99%), 141 h:1 min (98%), and 142 h:24 min (99%), respectively in the three centres. A valid measurement period was reached in 94%, 97%, and 94% of the patients and did not differ across sites (P = 0.53). The amount of physical activity did not differ across sites (mean steps per day, 4725 ± 3212, P = 0.58; mean PAL, 1.45 ± 0.20, P = 0.48). Multivariate linear regression analyses revealed significant associations of FEV1, 6-min walk distance, quadriceps strength, fibrinogen, health status, and dyspnoea with both steps per day and PAL. Previously unrecognized correlates of activity were grade of fatigue, degree of emphysema, and exacerbation rate.
CONCLUSIONS: The excellent compliance with wearing a physical activity monitor irrespective of study site and consistent associations with relevant disease characteristics support the use of activity monitoring as a valid outcome in multi-center studies. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22118987     DOI: 10.1016/j.rmed.2011.10.022

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  50 in total

1.  The Frailty Phenotype and Palliative Care Needs of Older Survivors of Critical Illness.

Authors:  Lauren R Pollack; Nathan E Goldstein; Wendy C Gonzalez; Craig D Blinderman; Mathew S Maurer; David J Lederer; Matthew R Baldwin
Journal:  J Am Geriatr Soc       Date:  2017-03-06       Impact factor: 5.562

2.  Physical Activity and Fatigue in Patients with Sarcoidosis.

Authors:  Thomas Bahmer; Henrik Watz; Maria Develaska; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Anne-Marie Kirsten
Journal:  Respiration       Date:  2017-11-09       Impact factor: 3.580

3.  Feasibility and acceptability of active for life with COPD, an intervention to increase light physical activity in people with COPD.

Authors:  Janet L Larson; Katelyn E Webster
Journal:  Heart Lung       Date:  2020-01-31       Impact factor: 2.210

4.  Measurement of daily physical activity using the SenseWear Armband: Compliance, comfort, adverse side effects and usability.

Authors:  Renae J McNamara; Ling Ling Y Tsai; Sally L Wootton; L W Cindy Ng; Marita T Dale; Zoe J McKeough; Jennifer A Alison
Journal:  Chron Respir Dis       Date:  2016-02-15       Impact factor: 2.444

5.  Biobehavioral Prognostic Factors in Chronic Obstructive Pulmonary Disease: Results From the INSPIRE-II Trial.

Authors:  James A Blumenthal; Patrick J Smith; Michael Durheim; Stephanie Mabe; Charles F Emery; Tereza Martinu; Philip T Diaz; Michael Babyak; Karen Welty-Wolf; Scott Palmer
Journal:  Psychosom Med       Date:  2016 Feb-Mar       Impact factor: 4.312

6.  Daily step counts in a US cohort with COPD.

Authors:  Marilyn L Moy; Valery A Danilack; Nicole A Weston; Eric Garshick
Journal:  Respir Med       Date:  2012-04-20       Impact factor: 3.415

7.  Physical activity and the frequency of acute exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  M Schönmann; N A Sievi; C F Clarenbach; T Brack; M Brutsche; M Frey; S Irani; J D Leuppi; J Ruediger; O Senn; R Thurnheer; M Kohler
Journal:  Lung       Date:  2014-12-13       Impact factor: 2.584

Review 8.  Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design.

Authors:  Rosita Zakeri; James A Levine; Gabriel A Koepp; Barry A Borlaug; Julio A Chirinos; Martin LeWinter; Peter VanBuren; Victor G Dávila-Román; Lisa de Las Fuentes; Prateeti Khazanie; Adrian Hernandez; Kevin Anstrom; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2015-01       Impact factor: 8.790

9.  Percent Emphysema and Daily Motor Activity Levels in the General Population: Multi-Ethnic Study of Atherosclerosis.

Authors:  Christian M Lo Cascio; Mirja Quante; Eric A Hoffman; Alain G Bertoni; Carrie P Aaron; Joseph E Schwartz; Mark V Avdalovic; Vincent S Fan; Gina S Lovasi; Steven M Kawut; John H M Austin; Susan Redline; R Graham Barr
Journal:  Chest       Date:  2016-12-06       Impact factor: 9.410

10.  Development of Respercise® a Digital Application for Standardizing Home Exercise in COPD Clinical Trials.

Authors:  John G Yonchuk; Divya Mohan; Nathan K LeBrasseur; Ashley R George; Sally Singh; Ruth Tal-Singer
Journal:  Chronic Obstr Pulm Dis       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.